About Peijia
Corporate Overview
Introduction of Achieva Medical
Milestones
Management Team
Awards and Recognitions
Social Responsibility
Diseases and Solutions
Valvular Heart Diseases
Stroke
Product Center
TAVR
Neurointerventional Procedural Products
Investor Relations
Corporate Information
Prospectus
Financial Reports
Announcements and Circulars
Presentation Materials
Corporate Governance
Investor Enquiries
News Center
Careers
Contact Us
简
繁
About Peijia
Corporate Overview
Introduction of Achieva Medical
Milestones
Management Team
Awards and Recognitions
Social Responsibility
Diseases and Solutions
Valvular Heart Diseases
Stroke
Product Center
TAVR
Neurointerventional Procedural Products
Investor Relations
Corporate Information
Prospectus
Financial Reports
Announcements and Circulars
Presentation Materials
Corporate Governance
Investor Enquiries
News Center
Careers
Contact Us
简
繁
About Peijia
Corporate Overview
Introduction of Achieva Medical
Milestones
Management Team
Awards and Recognitions
Social Responsibility
Diseases and Solutions
Valvular Heart Diseases
Stroke
Product Center
TAVR
Neurointerventional Procedural Products
Investor Relations
Corporate Information
Prospectus
Financial Reports
Announcements and Circulars
Presentation Materials
Corporate Governance
Investor Enquiries
News Center
Careers
Contact Us
News Center
Collaboration Strengthens Peijia’s Position for Competing in a Largely Untapped Market and Supports Global Expansion of HighLife’s Technology
2020-12-21
Peijia Medical Successfully Commenced Animal Study for its Mitral Valve Edge-to-Edge Repair Product
2020-12-04
Peijia Medical Successfully Listed on the Main Board of the Stock Exchange of Hong Kong
2020-05-15
Peijia Medical Announces Global Offering Results Offer Price is HK$15.36 per Offer Share, Commence Trading on the Main Board of the Hong Kong Stock Exchange On May 15, 2020
2020-05-14
